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Macrophages are essential effector cells of innate immunity that play a pivotal role in the recognition and
elimination of invasive microorganisms. Mediators released by activated macrophages orchestrate innate and
adaptive immune host responses. The cytokine macrophage migration inhibitory factor (MIF) is an integral
mediator of the innate immune system. Monocytes and macrophages constitutively express large amounts of
MIF, which is rapidly released after exposure to bacterial toxins and cytokines. MIF exerts potent proinflam-
matory activities and is an important cytokine of septic shock. Recent investigations of the mechanisms by
which MIF regulates innate immune responses to endotoxin and gram-negative bacteria indicate that MIF
acts by modulating the expression of Toll-like receptor 4, the signal-transducing molecule of the lipopolysac-
charide receptor complex. Given its role in innate immune responses to bacterial infections, MIF is a novel
target for therapeutic intervention in patients with septic shock.
The innate immune system is the first line of host de-
fense against infection [1–3]. Detection of invasive mi-
croorganisms by the innate immune system is mediated
by soluble factors, such as the lipopolysaccharide
(LPS)–binding protein (LBP) and by pattern-recogni-
tion receptors expressed on immune cells (e.g., CD14
and the Toll-like receptors [TLRs]). Binding of path-
ogens or microbial toxins to these receptors activates
the signal transduction pathways and transcription of
immune genes, resulting in the release of multiple ef-
fector molecules in the extracellular milieu, including
cytokines. Cytokines promote inflammation and or-
chestrate the host’s cellular and humoral responses that
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are aimed at the elimination or walling off of invasive
pathogens.
The cytokine macrophage migration inhibitory fac-
tor (MIF) was discovered nearly 40 years ago during
studies of delayed-type hypersensitivity reactions. MIF
was identified as a soluble nondialyzable factor released
by activated lymphocytes that inhibited the random
migration of peritoneal exudate cells—hence its name
[4, 5]. Over the ensuing 20 years, MIF was found to
exert macrophage activation functions, such as cell ad-
hesion, phagocytosis, and killing of tumor cells and
intracellular parasites [6]. However, the biologic activ-
ities attributed to MIF remained questionable, because
all studies were done with cell culture supernatants of
activated T cells containing numerous effector mole-
cules in addition to MIF. A human MIF cDNA was
cloned in 1989 [7], and shortly thereafter MIF was
rediscovered as a protein released in a hormone-like
fashion by anterior pituitary cells stimulated with en-
dotoxin (i.e., LPS) [8]. Invigorated by this observation,
investigations of MIF’s biochemical properties and bi-
ologic activities progressed rapidly once purified mouse
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and human recombinant MIF proteins and neutralizing anti-
MIF antibodies became available [8, 9].
MIF GENE AND PROTEIN: STRUCTURE,
HOMOLOGIES, AND BIOLOGIC ACTIVITIES
The human Mif gene is located on chromosome 22 (22q11.2)
and is composed of 3 exons separated by small introns [7, 9–11].
In all tissues examined by Northern blotting, a single MIF mRNA
was identified. Baseline MIF mRNA levels are elevated in several
organs including kidney, liver, and brain. In the mouse, the Mif
gene has been mapped to chromosome 10 [12]. More than 9
Mif pseudogenes have been identified in the mouse genome [13,
14]. In contrast, there are no Mif pseudogenes in the human
genome. Analyses of the sequences of the exons of mouse and
human Mif show a high degree of homology (70%–86%). Until
now, D-dopachrome tautomerase has been the only other human
gene found to share some degree of homology (∼30%) with Mif
[15]. This suggests that MIF does not belong to any of the well-
characterized cytokine superfamilies.
At the amino acid level, mouse and human MIF are 90%
identical. There is also 180% homology between mouse, rat,
gerbil, chicken, calf, and human MIF proteins, indicating that
MIF is highly conserved across species. Of note, MIF is identical
to a protein known as glycosylation-inhibiting factor, which
suppresses IgE synthesis by inhibiting the N-glycosylation of
IgE-binding factors and is associated with antigen-specific sup-
pressor activity [16]. As indicated, MIF shares a 33% aa se-
quence homology with D-dopachrome tautomerase [17].
Bioinformatic searches for MIF homologues in genome data-
bases have revealed the presence of MIF-like molecules in Cae-
norhabditis elegans and Arabidopsis thaliana and in filarial
parasites such as Wuchereria bancrofti, Brugia malayi, and Onch-
ocerca volvulus.
Crystallographic analyses of human and rat MIF strongly sug-
gest that MIF is a trimer with structural similarity to dopachrome
tautomerase and 3 microbial enzymes: 4-oxalocrotonate tauto-
merase, 5-carboxymethyl-2-hydroxymuconate isomerase, and
chorismate mutase [17–21]. In agreement with these observa-
tions, MIF exerts tautomerase activity and catalyzes the conver-
sion of 2-carboxy-2,3-dihydroindole-5,6-quinone (dopachrome)
into 5,6-dihydroxyindole-2-carboxylic acid [22, 23].
Other catalytic properties have been ascribed to MIF, in-
cluding the enolization of phenylpyruvate and the ketonization
of p-hydroxyphenylpyruvate [23] and a thiol-protein oxido-
reductase activity linked to a conserved Cys57-Ala-Leu-Cys60
(CALC) motif [24]. Although these findings suggest that MIF
is an enzyme, the physiologic relevance of these MIF enzymatic
activities remains unclear. Deletion or replacement of the N-
terminal proline of MIF abolished the tautomerase activity [25]
but not the capacity of MIF to inhibit monocyte migration
[26]. However, insertion of an alanine between the Pro-1 and
Met-2 of MIF abolished both the catalytic dopachrome tau-
tomerase activity and the glucocorticoid overriding activity of
MIF [27]. In contrast, the first 6 N-terminal residues were not
essential for the insulin-reducing oxidoreductase activity assay,
yet appeared to be required for full expression of 2-hydroxy-
ethyldisulfide activity, another assay for testing oxidoreductase
activity [28]. Chromosomal mapping indicates that the Mif and
dopachrome tautomerase genes are located in close proximity,
which suggests the possibility that both genes are duplications
of a common ancestral gene and have evolved to exert different
biologic functions.
CELLULAR SOURCES AND TISSUE
DISTRIBUTION OF MIF
MIF mRNA and protein are constitutively expressed by many
organs and cells, including brain (neurons of the cortex and
cerebellum, hypothalamus, hippocampus, pons, glial cells, and
ependyma), pituitary gland (corticotrophic and thyrotropic
cells), kidneys (mesangial and epithelial cells of the proximal
tubules, collecting ducts, glomeruli, and Bowman capsule),
lungs (alveolar macrophages and epithelial cells of the bronchi),
liver (Kuppfer cells, hepatocytes, and endothelium of the central
venules), spleen (white and red pulp), adrenal glands (zona
glomerulosa and zona fasciculata), skin (keratinocytes, seba-
ceous gland, and outer root sheet of the hair follicle), endo-
thelial cells, and fibroblasts [29].
MIF is also found in b cells of the islets of Langerhans of
the pancreas, where its production is regulated by glucose in
time- and concentration-dependent manners [30]. In turn, MIF
potentiates insulin secretion induced by glucose. Within the
immune system, MIF has been detected in monocytes, mac-
rophages, dendritic cells, T and B lymphocytes, eosinophils,
mast cells, basophils, and neutrophils. After administration of
LPS to rats, preformed MIF was rapidly released from all tissues
examined. The initial depletion phase was followed by the
strong induction of MIF mRNA, de novo synthesis of MIF
protein, and reconstitution of the intracellular MIF pool [29].
MIF AND INNATE IMMUNITY
Although MIF was first described as a T cell cytokine of the
adaptive immune system, it serves important functions within
the innate immune system. For 12 decades, the macrophage
was considered a major target of MIF action; therefore, it was
surprising to discover that monocytes and macrophages con-
stitutively express large amounts of MIF mRNA and protein
[31, 32]. Macrophage MIF is released after stimulation with
microbial products that include bacterial endotoxin (LPS) and
exotoxins (toxic shock syndrome toxin [TSST]–1 and strep-
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tococcal pyrogenic exotoxin A [SPEA]), malaria pigment, and
after exposure to gram-negative and gram-positive bacteria,
mycobacteria, and proinflammatory cytokines, such as tumor
necrosis factor (TNF)–a and interferon-g [31, 33, 34]. Many
of these stimuli induce a typical “bell-shaped” release of MIF
by macrophages with minimal production at the far end of the
dose-response curve.
Another unusual feature of MIF is that its secretion is in-
duced rather than inhibited by glucocorticoid hormones, as
with most cytokines [32, 35]. The dose-response curve of mac-
rophage MIF production induced by dexamethasone or cortisol
is also bell shaped, with the greatest release occurring at very
low glucocorticoid concentrations (1012–1014 M). Other in-
vestigators have made similar observations with synoviocytes
[36]. At first, this observation appeared to contradict the proin-
flammatory properties of MIF. However, MIF was subsequently
found to override the immunosuppressive effects of glucocor-
ticoids [32]. In vitro, MIF reverses glucocorticoid-induced in-
hibition of TNF-a and interleukin (IL)–1, -6, and -8 synthesis
by peripheral blood mononuclear cells and of cytosolic phos-
pholipase A2 activity and arachidonic acid release by fibroblasts
[37]. Likewise, in vivo, recombinant MIF reverses the protective
effects mediated by glucocorticoids in an experimental model
of lethal endotoxemia [32]. Supported by a rapidly growing
body of data [32, 37], a concept has emerged that MIF acts as
a physiologic antagonist of glucocorticoid activity and that MIF
and glucocorticoids operate in concert to regulate innate and
acquired immune responses.
During investigations into the role played by MIF in the
activation of the arachidonic acid–prostaglandins-leukotrienes
pathway in acute inflammation and sepsis, Mitchell et al. [37,
38] observed that the proinflammatory function and viability
of LPS-stimulated MIF-deficient macrophages was impaired,
compared with wild-type macrophages. In the absence of MIF,
macrophage survival was reduced as a result of the activation
of p53-mediated apoptosis, a finding in agreement with the
observation by Hudson et al. [39] of an inhibition of the tumor
suppressor p53 by MIF. MIF-mediated inhibition of p53 in
macrophages was found to be dependent on the induction of
arachidonic acid metabolism and cyclooxygenase-2 expression.
Thus, excessive production and release of MIF during inflam-
mation and sepsis may help sustain inflammation by prolong-
ing the lifespan of macrophages that would otherwise go into
apoptosis.
Studies conducted with antisense MIF macrophages and
macrophages from MIF knockout (MIF/) mice revealed an
important role for MIF in host responses to LPS and gram-
negative bacteria [40]. Compared with wild-type cells, MIF-
deficient macrophages were hyporesponsive to endotoxin and
gram-negative bacteria, as shown by a profound reduction of
NF-kB activity and cytokine production. In contrast, MIF-de-
ficient macrophages exhibit normal responses to gram-positive
bacteria (group A streptococci, Staphylococcus aureus, or Strep-
tococcus mitis), peptidoglycan, the yeast particle zymosan, and
phorbol 12-myristate 13-acetate plus calcium ionophore, which
indicates that the defective response is restricted to LPS and
gram-negative bacteria.
Impairment of the host defense capacity of MIF-deficient
macrophages is linked to a down-regulation of TLR4, the sig-
nal-transducing molecule of the LPS receptor complex. In con-
trast, expression of TLR2 is preserved in MIF antisense mac-
rophages, a finding that is congruous with normal responses
to gram-positive bacteria and yeast particles. Studies of the
molecular mechanism by which MIF modulates TLR4 expres-
sion indicate that reduced expression of MIF in macrophages
impairs basal activity of members of the Ets family of tran-
scription factors, which are critical for the transcription of the
mouse TLR4 gene, and results in reduced expression of TLR4
protein and defective innate immune response to LPS and
gram-negative bacteria. The results also provide a mechanism
whereby MIF/ mice are resistant to endotoxic shock and a
rationale for the intriguing observation that MIF is expressed
constitutively by macrophages and by tissues in close proximity
with our natural environment. As shown in figure 1, by up-
regulating the basal expression of TLR4 in resting macrophages,
MIF facilitates the recognition of endotoxin-containing bacteria
and enables innate immune cells to rapidly release proinflam-
matory cytokines that are essential for mounting the host de-
fensive response.
MIF IN SEPSIS
The fact that MIF exerted potent proinflammatory activities
and served an important function in innate immune responses
of macrophages to microbial products strongly suggested a role
for MIF in sepsis. This hypothesis was verified in experimental
models of septic shock and in humans with bacterial sepsis.
Although the administration of large quantities of recombinant
MIF protein was not lethal when given alone, coinjection of
MIF and LPS increased mortality, compared with LPS alone
[8]. In contrast, neutralization of MIF activity with anti-MIF
antibodies attenuated TNF-a production and saved mice from
endotoxic shock. Similar results were obtained with MIF/
mice [41].
Resistance to lethal endotoxemia was associated with reduced
circulating concentrations of TNF-a and delayed appearance
of blood IL-12. MIF is also implicated in the pathogenesis of
gram-positive toxic shock syndromes. Low concentrations of
TSST-1 or SPEA stimulated MIF production from macro-
phages, and prophylactic administration of anti-MIF antibodies
prevented death from toxic shock syndrome caused by the
administration of TSST-1 to d-galactosamine–sensitized mice
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Figure 1. Role of the cytokine migration inhibitory factor (MIF) in recognition of endotoxin and gram-negative bacteria by macrophages. MIF, a
trimeric molecule by crystallography, promotes the recognition of endotoxin-containing elements by up-regulating the basal expression of Toll-like
receptor (TLR) 4 mRNA and protein. MIF is constitutively expressed by quiescent macrophages and may exert its effects via a direct intracellular
pathway or by being first released from macrophages to then act in an autocrine fashion by binding to an unidentified putative MIF receptor. TLR4
is a signal-transducing molecule of the lipopolysaccharide (LPS; a gram-negative bacteria) receptor complex. MIF effects on Tlr4 gene transcription
are mediated by transcription factors of the Ets family. CD14, surface antigen expressed on myeloid cells that binds LPS-LBP complexes; LBP, LPS-
binding protein; MD-2, protein associated with TLR4 extracellular domain that amplifies responses to LPS
[33]. Likewise, compared with wild-type mice, MIF/ mice
were resistant to exposure to lethal doses of staphylococcal
enterotoxin B [41]. Taken together, these results show that MIF
is an important mediator of the pathogenesis of toxic shock
syndrome induced by gram-negative endotoxin and gram-pos-
itive exotoxins.
MIF contributes to the pathogenesis of experimental sepsis
induced by live bacteria. MIF concentrations were increased in
the peritoneal fluid and in the systemic circulation of mice
infected with Escherichia coli, and polymicrobial peritonitis and
neutralization of MIF activity with anti-MIF antibodies pro-
tected mice from septic death [42]. Of note, in the cecal ligation
and puncture (CLP) model, mice were protected even when
treatment was started 8 h after the onset of bacterial peritonitis.
The fact that mice could be rescued despite delayed adminis-
tration of anti-MIF therapy is an important finding if one
contemplates the possibility of using anti-MIF treatment strat-
egies in humans. Indeed, antisepsis therapies will always be
initiated after the onset of infection in patients who are ad-
mitted with severe sepsis and septic shock.
In previous studies, mice with compromised innate immune
responses (e.g., those treated with anti-LBP, anti-CD14 anti-
bodies, or with deletion of the TNF-a gene or type 1 TNF
receptor) had increased susceptibility to bacterial sepsis [43–
47]. As anticipated, TNF-a knockout mice were very sensitive
to CLP and succumbed quickly to uncontrolled infection. Re-
markably, treatment with a single dose of anti-MIF monoclonal
antibodies given after CLP protected mice from death and in-
creased survival from none to 62%. Thus, blocking MIF activity
saved these severely immunocompromised mice from lethal
septic shock. Treatment with anti-MIF antibodies was associ-
ated with a reduction of plasma TNF-a concentrations and
circulating bacterial counts in the E. coli peritonitis model.
However, TNF-a and E. coli were not primary targets of anti-
MIF therapy in these sepsis models. Indeed, anti-MIF therapy
protected mice from death, even in the absence of TNF-a, and
the possibility of a direct causal relationship between blockade
of MIF activity and reduction of circulating bacteria was ruled
out by in vitro studies [42].
Similar to findings in the endotoxic shock model, increasing
the levels of MIF with a bolus injection of recombinant MIF
at the onset of infection increased the mortality in the E. coli
peritonitis model (21% in mice exposed to E. coli alone vs.
62% in mice coinjected with recombinant MIF and E. coli;
). Thus, elevated tissue or circulating MIF concentra-Pp .008
tions is harmful during the course of an acute infection.
Consistent with this hypothesis, high MIF concentrations
have been detected in the circulation of patients with severe
sepsis or septic shock caused by gram-negative and -positive
bacteria. Moreover, sicker patients had the highest MIF plasma
MIF in Sepsis • JID 2003:187 (Suppl 2) • S389
concentrations. Median plasma MIF levels were 17.8 ng/mL
(range, 6.6–154.4 ng/mL) in patients with septic shock and 12.2
ng/mL in patients with severe sepsis (range, 6.2–141.8 ng/mL),
compared with only 3 ng/mL in healthy persons (range, 1.9–5.4
ng/mL; ) [42]. Similarly, MIF serum levels measuredPp .001
on admission to an intensive care unit were higher in patients
with septic shock ( ) ( ng/mL) than inmean SD 14.3 4.5
trauma patients ( ng/mL) or control patients (3.1 1.7 2.5
1 ng/mL; ) [48]. In patients with septic shock, MIF2. P ! .01
concentrations were ng/mL in nonsurvivors and18.4 4.8
ng/mL in survivors ( ). Likewise, MIF con-10.2 4.2 Pp .001
centrations were higher in patients with adult respiratory dis-
tress syndrome (ARDS) than in those without ARDS (19.4
vs. ng/mL, respectively; ). By logistic re-4.7 9.2 4.2 Pp .12
gression analysis, the serum concentrations of MIF are a better
parameter than ARDS for predicting a patient’s outcome. In
addition, in patients with sepsis, MIF levels are correlated with
cortisol or IL-6 [48], a finding that is in agreement with our
previous observations of parallel increases of MIF and gluco-
corticoids in the systemic circulation during inflammation, in-
fection, and stress [32, 42].
CONCLUSIONS
As anticipated because of its potent proinflammatory proper-
ties, MIF is an important mediator of sepsis in experimental
models of infection and in humans with severe sepsis or septic
shock. Immunoneutralization of MIF or deletion of the Mif
gene protected mice against lethal endotoxemia, gram-positive
toxic shock syndromes, and experimental bacterial peritonitis;
however, administration of recombinant MIF increased the
mortality of endotoxemia and bacterial sepsis. Likewise, high
concentrations of MIF were detected in the systemic circulation
of patients with severe sepsis and septic shock and were as-
sociated with patient outcome. During sepsis, MIF may en-
danger life when expressed in large quantities. Anti-MIF strat-
egies, which interfere either with MIF production or with MIF
activity once it is released in the extracellular milieu, may have
a role in the care of patients with septic shock.
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